Citalopram

Generic Name
Citalopram
Brand Names
Celexa, Ctp
Drug Type
Small Molecule
Chemical Formula
C20H21FN2O
CAS Number
59729-33-8
Unique Ingredient Identifier
0DHU5B8D6V
Background

Citalopram is an antidepressant belonging to the class of selective serotonin-reuptake inhibitors (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs. Citalopram enhances serotonergic transmission through the i...

Indication

Citalopram is approved by the FDA for treating adults with major depressive disorder. It has also been used off-label to treat various diseases, including but not limited to sexual dysfunction, ethanol abuse, psychiatric conditions such as obsessive-compulsive disorder (OCD), social anxiety disorder, panic disorder, and diabetic neuropathy.

Associated Conditions
Alcohol Abuse, Anorexia Nervosa (AN), Binge Eating Disorder (BED), Bulimia Nervosa, Depression, Diabetic Neuropathies, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Post Traumatic Stress Disorder (PTSD), Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD), Separation Anxiety Disorder, Social Anxiety Disorder (SAD)
Associated Therapies
-
Clinical Trials
Related News

Pharmacokinetic Drug-drug Interaction Study Between RaltEgravir and CITALopram in Healthy Subjects (RECITAL).

Phase 1
Completed
Conditions
HIV
Depression
Interventions
Drug: raltegravir
Drug: citalopram
First Posted Date
2013-11-08
Last Posted Date
2020-10-19
Lead Sponsor
Radboud University Medical Center
Target Recruit Count
24
Registration Number
NCT01978782
Locations
🇳🇱

CRCN Radboud university medical center, Nijmegen, Netherlands

A Study to Evaluate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of JNJ-404118413 in Healthy Male Patients

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: JNJ-40411813
Drug: Placebo
Drug: Citalopram
First Posted Date
2013-09-26
Last Posted Date
2013-09-26
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
18
Registration Number
NCT01951053

Antidepressants, Emotions and Personality

Not Applicable
Completed
Conditions
Antidepressive Agents, Second-Generation
Interventions
Drug: Placebo
Drug: Citalopram
First Posted Date
2013-09-19
Last Posted Date
2013-09-19
Lead Sponsor
University of Oxford
Target Recruit Count
42
Registration Number
NCT01946607
Locations
🇬🇧

University of Oxford, Department of Psychiatry, Warneford Hospital, Oxford, Oxfordshire, United Kingdom

The Efficacy of Citalopram Treatment in Acute Stroke

Phase 2
Completed
Conditions
Stroke, Ischemic
Interventions
Drug: Placebo
Drug: Citalopram
First Posted Date
2013-09-09
Last Posted Date
2017-02-24
Lead Sponsor
University of Aarhus
Target Recruit Count
642
Registration Number
NCT01937182
Locations
🇩🇰

Aalborg University Hospital, Department of Neurology, Aalborg, Denmark

🇩🇰

Aarhus University Hospital, Department of Neurology, Aarhus, Denmark

🇩🇰

Glostrup University Hospital, Department of Neurology, Glostrup, Denmark

Placebo Effects in the Treatment of Depression: Cognitive and Neural Mechanisms

Phase 4
Completed
Conditions
Major Depressive Disorder
Interventions
Drug: Citalopram
First Posted Date
2013-08-08
Last Posted Date
2020-03-09
Lead Sponsor
New York State Psychiatric Institute
Target Recruit Count
65
Registration Number
NCT01919216
Locations
🇺🇸

New York State Psychiatric Institute, New York, New York, United States

Interpersonal Psychotherapy for Treatment Resistant Depression

First Posted Date
2013-07-11
Last Posted Date
2013-07-11
Lead Sponsor
Hospital de Clinicas de Porto Alegre
Target Recruit Count
74
Registration Number
NCT01896349
Locations
🇧🇷

Federal University of Rio Grande do Sul / Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil

Algorithm Guided Treatment Strategies for Major Depressive Disorder

First Posted Date
2013-01-10
Last Posted Date
2013-01-10
Lead Sponsor
Shanghai Mental Health Center
Target Recruit Count
1080
Registration Number
NCT01764867
Locations
🇨🇳

Shanghai Mental Health Center, Shanghai, China

Double-Blind Treatment of Major Depressive Disorder With Vilazodone

Phase 2
Completed
Conditions
Major Depressive Disorder
Interventions
Drug: Vilazodone
Drug: Citalopram
First Posted Date
2012-12-05
Last Posted Date
2023-02-23
Lead Sponsor
University of Chicago
Target Recruit Count
79
Registration Number
NCT01742832
Locations
🇺🇸

University of Chicago, Chicago, Illinois, United States

Pilot Study to Evaluate Individualized Choice of Antidepressants in Patients With Cancer

Early Phase 1
Completed
Conditions
Neoplasms
Major Depressive Disorder
Interventions
Drug: Mirtazapine
Drug: Citalopram
First Posted Date
2012-11-12
Last Posted Date
2017-03-13
Lead Sponsor
UNC Lineberger Comprehensive Cancer Center
Target Recruit Count
21
Registration Number
NCT01725048
Locations
🇺🇸

University of North Carolina Hospital, Chapel Hill, North Carolina, United States

Citalopram for Sx/Util in Acute Coronary Syndrome Patients

Phase 1
Withdrawn
Conditions
Acute Coronary Syndrome
Interventions
Drug: Citalopram
First Posted Date
2012-08-17
Last Posted Date
2022-12-09
Lead Sponsor
Henry Ford Health System
Registration Number
NCT01667744
Locations
🇺🇸

Henry Ford Hospital, Detroit, Michigan, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy